Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [
18F-FDG
68Ga-FAPI
MCRPC
PSMA
Prostate cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
01
05
2024
accepted:
16
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
In metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [ Patients with advanced, progressive mCRPC underwent clinical [ In ten patients, 472 lesions were detected on all imaging modalities (miTNM regions: M1b: 327 (69.3%), M1a: 95 (20.1%), N1: 26 (5.5%), M1c: 18 (3.8%), T: 5 (1.1%) and Tr: 1 (0.2%). [ Through whole-body imaging, we identify considerable inter- and intra-patient heterogeneity of mCRPC and potential imaging phenotypes. Regarding uptake and tumour detection, [
Identifiants
pubmed: 39207485
doi: 10.1007/s00259-024-06891-8
pii: 10.1007/s00259-024-06891-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.
doi: 10.1016/S0140-6736(17)33326-3
pubmed: 29395269
pmcid: 5879496
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survivial analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Yadav MP, Ballal S, Bal C, et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med. 2020;45:19–31.
doi: 10.1097/RLU.0000000000002833
pubmed: 31789908
Bakht MK, Yamada Y, Ku S-Y, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4:699–715.
doi: 10.1038/s43018-023-00539-6
pubmed: 37038004
pmcid: 10867901
Sayar E, Patel RA, Coleman IM, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;10: e162907.
doi: 10.1172/jci.insight.162907
Sheehan B, Neeb A, Buroni L, et al. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clin Cancer Res. 2022;28:3104–15.
doi: 10.1158/1078-0432.CCR-21-4531
pubmed: 35552383
pmcid: 9365343
Frankenstein Z, Basanta D, Franco OE, et al. Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression. Nat Ecol Evol. 2020;4:870–84.
doi: 10.1038/s41559-020-1157-y
pubmed: 32393869
pmcid: 11000594
Jadvar H. The VISION Forward: Recognition and Implication of PSMA-/ 18 F-FDG+ mCRPC. J Nucl Med. 2022;63–812–815.
doi: 10.2967/jnumed.121.263274
pubmed: 34933889
pmcid: 9157736
Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastastic castration-resistant prostate cancer (TheraP): a randomized, open-label, phase 2 trial. Lancet. 2021;397:797–804.
doi: 10.1016/S0140-6736(21)00237-3
pubmed: 33581798
Pouliot F, Saad F, Rousseau É, et al. Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC). JCO. 2024;42:31.
doi: 10.1200/JCO.2024.42.4_suppl.31
Liu C, Liu T, Zhang J, Baum RP, Yang Z. Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy. Clin Nucl Med. 2019;44:876–8.
doi: 10.1097/RLU.0000000000002780
pubmed: 31584494
Hintz HM, Gallant JP, Vander Griend DJ, et al. Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography. Clin Cancer Res. 2020;26:4882–91.
doi: 10.1158/1078-0432.CCR-20-1358
pubmed: 32636317
pmcid: 7683011
Kesch C, Yirga L, Dendl K, et al. High fibroblast-activation-protein expression in castration resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J of Nucl Med Mol Imaging. 2021;49:385–9.
doi: 10.1007/s00259-021-05423-y
Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of Fibroblast Activation Protein is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival. Genes (Basel). 2022;13:135.
doi: 10.3390/genes13010135
pubmed: 35052475
Isik EG, Has-Simsek D, Sanli O, Sanli Y, Kuyumcu S. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. Clin Nucl Med. 2022;47:e54–5.
doi: 10.1097/RLU.0000000000003837
pubmed: 34392294
Aryana K, Manafi-Farid R, Amini H, Divband G, Moghadam SZ. 68Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression. Clin Nucl Med. 2022;47:972–3.
doi: 10.1097/RLU.0000000000004315
pubmed: 35777753
Kratochwil C, Flechsig P, Lindner T, et al. Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60:801–5.
doi: 10.2967/jnumed.119.227967
pubmed: 30954939
pmcid: 6581228
Fendler WP, Pabst KM, Kessler L, et al. Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clin Cancer Res. 2022;28:4346–53.
doi: 10.1158/1078-0432.CCR-22-1432
pubmed: 35833949
pmcid: 9527500
Assadi M, Rekabpour SJ, Jafari E, et al. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients with Relapsed or Refractory Cancers: A Preliminary Study. Clin Nucl Med. 2021;46:e523–30.
doi: 10.1097/RLU.0000000000003810
pubmed: 34269729
Laudicella R, Spataro A, Crocè L, et al. Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics. Diagnostics (Basel). 2023;13:1175.
doi: 10.3390/diagnostics13061175
pubmed: 36980482
Nader M, Valla DF, Vriamont C, et al. [
doi: 10.1016/j.nucmedbio.2022.04.010
pubmed: 35533534
Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline / SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466–86.
doi: 10.1007/s00259-022-06089-w
pubmed: 36604326
pmcid: 10027805
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG-PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59:469–78.
doi: 10.2967/jnumed.117.198119
pubmed: 29123012
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;16:1091–103.
doi: 10.1056/NEJMoa2107322
Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate Cancer Theranostics: PSMA Targeted Therapy. PET Clin. 2021;16:391–6.
doi: 10.1016/j.cpet.2021.03.004
pubmed: 34053583
Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
doi: 10.1007/s00259-020-05160-8
pubmed: 33336265
Chen R, Wang Y, Zhu Y, et al. The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63:69–75.
doi: 10.2967/jnumed.120.262250
pubmed: 34980667
pmcid: 8717199
Kuo PH, Morris M, Kendi AT, et al. Association of baseline quantitative [68Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [177Lu]Lu-PSMA-617: a VISION sub-study. Eur J Nucl Med Mol Imaging. 2023;50(Suppl. 1):155.
Hotta M, Gafita A, Czernin J, Calais J. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022;63:1484–8.
doi: 10.2967/jnumed.121.263441
pubmed: 35273096